Certolizumab Pegol

FA complementation group B ; Homo sapiens







36 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 32207094 Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis. 2020 Apr 2
2 33116155 Improvement of Certolizumab Fab' properties by PASylation technology. 2020 Oct 28 1
3 27567553 Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. 2018 Jan 1
4 29860435 TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism. 2018 Aug 29 1
5 28124979 Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. 2017 Jan 23 1
6 28712320 Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study. 2017 Nov 2
7 27464588 Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. 2016 Dec 1
8 25586216 Evaluation of pharmacokinetics and pharmacodynamics and clinical efficacy of certolizumab pegol for Crohn's disease. 2015 Feb 1
9 26316054 Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis. 2015 Oct 2
10 24687236 Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice. 2014 Apr 1
11 23620660 Profile of certolizumab and its potential in the treatment of psoriatic arthritis. 2013 2
12 23752881 Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. 2013 Sep 1
13 22413944 Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. 2012 Jul 1
14 21507990 The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. 2011 Jul 3
15 21642014 Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. 2011 Aug 2
16 21794764 [Certolizumab pegol]. 2011 Mar 1
17 27790005 Certolizumab in the long-term treatment of rheumatoid arthritis. 2011 1
18 19885906 Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. 2010 May 1
19 20096379 Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. 2010 Apr 1
20 20674798 Pulmonary infectious complications of tumor necrosis factor blockade. 2010 Sep 1
21 21079302 Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block. 2010 Nov-Dec 1
22 22915918 Prefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritis. 2010 2
23 19222517 New biologics for psoriasis and psoriatic arthritis. 2009 Jan-Feb 1
24 19491672 Infectious complications of tumor necrosis factor blockade. 2009 Aug 1
25 19894782 Certolizumab pegol: in rheumatoid arthritis. 2009 1
26 20477691 Certolizumab pegol for the treatment of Crohn's disease. 2009 Nov 1
27 21694828 New biologics in the management of Crohn's disease: focus on certolizumab pegol. 2009 1
28 19180261 Certolizumab pegol in Crohn's disease. 2008 Nov 1
29 21221187 Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease. 2008 Feb 29 2
30 17516714 Certolizumab pegol: in Crohn's disease. 2007 1
31 17634458 Certolizumab pegol for the treatment of Crohn's disease. 2007 Jul 19 1
32 17634459 Maintenance therapy with certolizumab pegol for Crohn's disease. 2007 Jul 19 1
33 17722511 Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). 2007 2
34 20477019 Treatment of Crohn's disease with certolizumab pegol. 2007 Sep 3
35 15934837 CDP-870 (certolizumab) in rheumatoid arthritis. 2005 Apr 1
36 15606396 Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. 2004 Dec 1